P. Hohl

680 total citations
26 papers, 578 citations indexed

About

P. Hohl is a scholar working on Epidemiology, Pharmacology and Molecular Medicine. According to data from OpenAlex, P. Hohl has authored 26 papers receiving a total of 578 indexed citations (citations by other indexed papers that have themselves been cited), including 12 papers in Epidemiology, 11 papers in Pharmacology and 11 papers in Molecular Medicine. Recurrent topics in P. Hohl's work include Antibiotic Resistance in Bacteria (11 papers), Antibiotics Pharmacokinetics and Efficacy (11 papers) and Pneumonia and Respiratory Infections (5 papers). P. Hohl is often cited by papers focused on Antibiotic Resistance in Bacteria (11 papers), Antibiotics Pharmacokinetics and Efficacy (11 papers) and Pneumonia and Respiratory Infections (5 papers). P. Hohl collaborates with scholars based in Switzerland, Germany and United States. P. Hohl's co-authors include Ingrid Heinze‐Krauss, Peter Angehrn, Rudolf Then, Malcolm G. P. Page, Paul Hebeisen, José M. Entenza, Philippe Moreillon, M. P. Glauser, Reno Frei and Christian Herzog and has published in prestigious journals such as Clinical Infectious Diseases, The American Journal of Medicine and Antimicrobial Agents and Chemotherapy.

In The Last Decade

P. Hohl

26 papers receiving 537 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
P. Hohl Switzerland 11 271 260 232 231 97 26 578
E Huczko United States 15 317 1.2× 345 1.3× 273 1.2× 356 1.5× 86 0.9× 20 806
M. Husson Belgium 13 175 0.6× 205 0.8× 176 0.8× 165 0.7× 96 1.0× 35 499
Mary S. Barrett United States 13 167 0.6× 226 0.9× 163 0.7× 232 1.0× 84 0.9× 31 473
B Kolek United States 13 173 0.6× 307 1.2× 294 1.3× 206 0.9× 89 0.9× 16 637
C E Fasching United States 14 125 0.5× 225 0.9× 181 0.8× 195 0.8× 94 1.0× 22 575
Elizabeth Gradelski United States 13 135 0.5× 261 1.0× 260 1.1× 129 0.6× 118 1.2× 19 513
E Vallée France 16 157 0.6× 307 1.2× 266 1.1× 419 1.8× 35 0.4× 31 642
C T Eliopoulos United States 8 272 1.0× 178 0.7× 189 0.8× 171 0.7× 177 1.8× 8 507
Karen Amsler United States 10 257 0.9× 233 0.9× 231 1.0× 157 0.7× 140 1.4× 15 593
M Meyran France 9 104 0.4× 108 0.4× 229 1.0× 136 0.6× 60 0.6× 63 414

Countries citing papers authored by P. Hohl

Since Specialization
Citations

This map shows the geographic impact of P. Hohl's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by P. Hohl with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites P. Hohl more than expected).

Fields of papers citing papers by P. Hohl

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by P. Hohl. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by P. Hohl. The network helps show where P. Hohl may publish in the future.

Co-authorship network of co-authors of P. Hohl

This figure shows the co-authorship network connecting the top 25 collaborators of P. Hohl. A scholar is included among the top collaborators of P. Hohl based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with P. Hohl. P. Hohl is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Widmer, Andreas F., P. Hohl, Stefan Dirnhofer, et al.. (2007). Legionella bozemanii, an Elusive Agent of Fatal Cavitary Pneumonia. Infection. 35(3). 180–181. 5 indexed citations
2.
Pallarés, Román, Olga Capdevila, Josefina Liñares, et al.. (2002). The effect of cephalosporin resistance on mortality in adult patients with nonmeningeal systemic pneumococcal infections. The American Journal of Medicine. 113(2). 120–126. 45 indexed citations
3.
Hebeisen, Paul, Ingrid Heinze‐Krauss, Peter Angehrn, et al.. (2001). In Vitro and In Vivo Properties of Ro 63-9141, a Novel Broad-Spectrum Cephalosporin with Activity against Methicillin-Resistant Staphylococci. Antimicrobial Agents and Chemotherapy. 45(3). 825–836. 188 indexed citations
4.
Hohl, P., et al.. (1998). Escherichia coli producing a cephamycinase (CMY-2) from a patient from the Libyan–Tunisian border region. Clinical Microbiology and Infection. 4(3). 168–170. 10 indexed citations
5.
Lucena, Ricardo Barbosa, et al.. (1994). Cefetamet pivoxil in the treatment of uncomplicated gonorrhea. Diagnostic Microbiology and Infectious Disease. 19(2). 121–127. 1 indexed citations
6.
Jones, Ronald N., et al.. (1993). Interlaboratory variations of fluoroquinolone susceptibility testing. Diagnostic Microbiology and Infectious Disease. 17(3). 225–232. 5 indexed citations
7.
Pastoris, Maddalena Castellani, P. Benedetti, Donato Greco, et al.. (1992). Six cases of travel-associated legionnaires' disease in Ischia involving four countries. Infection. 20(2). 73–77. 5 indexed citations
8.
9.
Hohl, P., et al.. (1991). In vitro susceptibility of 33 clinical case isolates of Xanthomonas maltophilia. Diagnostic Microbiology and Infectious Disease. 14(5). 447–450. 27 indexed citations
10.
11.
Hohl, P., et al.. (1990). In vitro Activity of Fleroxacin against Aerobic Gram-Positive Bacteria Including <i>Corynebacterium jeikeium</i>. Chemotherapy. 36(6). 403–406. 4 indexed citations
12.
13.
Angehrn, Peter, P. Hohl, & Rudolf Then. (1989). In vitro antibacterial properties of cefetamet and in vivo activity of its orally absorbable ester derivative, cefetamet pivoxil. European Journal of Clinical Microbiology & Infectious Diseases. 8(6). 536–543. 21 indexed citations
14.
Hohl, P., et al.. (1989). Cefetamet pivoxil (Ro 15-8075) and amoxicillin in the treatment of bacterial exacerbations of chronic bronchial disease--preliminary results.. PubMed. 1(4 Suppl). 778–9. 1 indexed citations
15.
Salfinger, Max, et al.. (1988). Comparative in-vitro activity of fleroxacin and other 6-fluoroquinolones against mycobacteria. Journal of Antimicrobial Chemotherapy. 22(Supplement_D). 55–63. 7 indexed citations
16.
Herzog, Christian, et al.. (1988). Fleroxacin: in-vitro activity worldwide against 20,807 clinical isolates and comparison to ciprofloxacin and norfloxacin. Journal of Antimicrobial Chemotherapy. 22(Supplement_D). 3–17. 32 indexed citations
17.
Hohl, P., et al.. (1988). Cefetamet pivoxil: Bacteriostatic and bactericidal activity of the free acid against 355 gram-negative rods. Infection. 16(3). 194–198. 5 indexed citations
18.
Hohl, P., et al.. (1988). Effect of method, medium, pH and inoculum on the in-vitro antibacterial activities of fleroxacin and norfloxacin. Journal of Antimicrobial Chemotherapy. 22(Supplement_D). 71–80. 14 indexed citations
19.
Hohl, P., et al.. (1987). In vitro activity of the new quinolone RO 23-6240 (AM-833) and the new cephalosporins RO 15-8074 and RO 19-5247 (T-2525) againstMycobacterium fortuitum andMycobacterium chelonae. European Journal of Clinical Microbiology & Infectious Diseases. 6(4). 487–488. 8 indexed citations
20.
Hohl, P., et al.. (1983). Infections Due to Wangiella dermatitidis in Humans: Report of the First Documented Case from the United States and a Review of the Literature. Clinical Infectious Diseases. 5(5). 854–864. 40 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by E Huczko Breakdown of academic impact, for papers by M. Husson Breakdown of academic impact, for papers by Mary S. Barrett Breakdown of academic impact, for papers by B Kolek Breakdown of academic impact, for papers by C E Fasching Breakdown of academic impact, for papers by Elizabeth Gradelski Breakdown of academic impact, for papers by E Vallée Breakdown of academic impact, for papers by C T Eliopoulos Breakdown of academic impact, for papers by Karen Amsler Breakdown of academic impact, for papers by M Meyran
Rankless by CCL
2026